{"id":"NCT01294436","sponsor":"AstraZeneca","briefTitle":"Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus","officialTitle":"A Long Term Open Label Study to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy or Combination Therapies With Anti-diabetic Drugs in Japanese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2011-02-11","resultsPosted":"2013-09-16","lastUpdate":"2013-12-17"},"enrollment":728,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type2 Diabetes","High Blood Sugar"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":[]}],"arms":[{"label":"Open label treatment","type":"EXPERIMENTAL"}],"summary":"This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who have inadequate blood sugar control on diet and exercise or on other anti-diabetic treatment will be included in this study.","primaryOutcome":{"measure":"Proportion of Participants With Adverse Events","timeFrame":"Long-term treatment up to 52 weeks","effectByArm":[{"arm":"Monotherapy","deltaMin":79.1,"sd":null},{"arm":"All Combination Therapies","deltaMin":72.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":38,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":249},"commonTop":["NASOPHARYNGITIS","POLLAKIURIA"]}}